PerkinElmer predicts 12% growth in Q2

By staff writers

July 14, 2020 -- PerkinElmer has announced an updated outlook for the second quarter of 2020, predicting 12% revenue growth.

For the quarter (end-July 5), the company said it anticipates roughly 12% growth in reported and organic revenue due to better-than-expected demand for COVID-19-related products. Products that aid with COVID-19 testing contributed approximately $190 million in revenue for the quarter, the company noted.

PerkinElmer announced it will release its full second-quarter results after market close on July 28.

COVID-19 powers $5B in molecular diagnostics market growth
The worldwide demand for COVID-19 tests has materialized rapidly from nothing and is on course to become a multibillion-dollar market in 2020, writes...
PerkinElmer says it's not target of federal probe
PerkinElmer on May 18 said that while the company had received subpoenas from federal investigators looking into healthcare fraud at medical labs, the...
PerkinElmer Q1 revenues edge up, profit edges down
In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped.
PerkinElmer gets regulatory nod in U.S. for coronavirus test
PerkinElmer is among the latest vendors to receive an emergency use authorization from the U.S. Food and Drug Administration for a reverse transcription...

Copyright © 2020

Last Updated ls 7/14/2020 10:40:17 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.